Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inkef Capital
BioCentury | Jun 21, 2024
Finance
Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M
Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
BioCentury | Nov 16, 2023
Deals
Nov. 15 Quick Takes: Kite, Arcellx expand CAR T deal
Plus: Gilde closes new €740M fund and updates from RefleXion, NMD, Lenz-Graphite, Cytovale, T-Therapeutics, Vittoria, CorMedix
BioCentury | Apr 6, 2023
Management Tracks
After leading CinCor to exit, de Garidel finds next CEO role at Abivax
Plus: INKEF’s Bulthuis joins Syncona and updates from Rocket, NGM, SparingVision, Walden and more
BioCentury | Jun 10, 2022
Finance
Predicting the fallout from private equity’s inroads into biotech
Dynamics include increased growth capital, shifting opportunities in company creation
BioCentury | May 6, 2022
Finance
How early-stage VCs are adjusting in a bear market
How the bear market is shifting the dynamics of syndicate building for early-stage VCs
BioCentury | Apr 27, 2022
Data Byte
Europe’s biggest biotech venture rounds so far this year
Eight European therapeutics developers have raised venture rounds of at least $50M year-to-date
BioCentury | Mar 29, 2022
Data Byte
Three radiotherapy companies have raised over $200M in 1Q22
March fund-raisings equate to over 80% of 2021’s total venture capital raised and almost two-thirds of 2020’s total
BioCentury | Mar 18, 2022
Finance
Precirix building out radiotherapy platform with €80M series B
The Belgian company is branching out into alpha emitters and growing its geographical footprint
BioCentury | Mar 11, 2022
Deals
March 10 Quick Takes: Scenic heads to clinic with $31M series A
Plus AbbVie, Venatorx meet in Phase III and updates from MorphoSys, RefleXion, TG Therapeutics, Xeris and more
BioCentury | Feb 23, 2022
Finance
Jeito joins NMD’s syndicate to help Danish play build clinical, U.S. strategy
The French VC attracted by NMD’s ability to identify patients with severe neuromuscular disease likely to respond to therapy
Items per page:
1 - 10 of 43